HLA-DRB1 and myeloid sarcoma: In multinomial logistic regression correcting for age and gender, there was no evidence for a significant association of HLA DRB1*1501 status (52.3% in progressive MS vs. 51.3% in non-progressive MS, p = 0.78) with non-progressive MS/progressive MS status.